Pharvaris NV
PHVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.53B
Close$
$5.74
84.5% downside
Current Fair Value
84.5% downsideOvervalued by 84.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.53 Billion |
|---|---|
| Enterprise Value | $2.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | -2.33 |
| Outstanding Shares | 68,072,000 |
Return
| Return on Equity | -57.03% |
|---|---|
| Return on Assets | -52.20% |
| Return on Invested Capital | -60.76% |
Valuation & Multiples
| P/E Ratio | -11.5 |
|---|---|
| PEG | -221.41 |
| Price to Sales | - |
| Price to Book Ratio | 9.25 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.11 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.87
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.6396▲ 363.96% |
|---|---|
| Total Calls | 22,200▲ Infinity% |
| Total Puts | 80,800▼ 7.13% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.97%▲ 0.37% |
|---|---|
| Total Invested | $2.25B▲ 35.36% |
| Investors Holding | 130▲ 18.00% |
ESG Score
No data
About Pharvaris NV
14 employeesPharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alterna...